OKYO PHARMA LTD SEC Filings

OKYO Pharma Limited reports that the U.S. Food and Drug Administration has authorized a single-patient expanded access (compassionate use) IND for its drug candidate urcosimod (0.05%) to treat a patient with severe neuropathic corneal pain who has limited options and no FDA-approved treatments available. The IND was submitted by Pedram Hamrah, MD, at the University of South Florida, and urcosimod is being provided by OKYO under this authorization.

The company notes that urcosimod previously received the first IND to treat neuropathic corneal pain and was granted FDA fast track designation. OKYO recently reported positive pain-reduction data in an 18-patient Phase 2 trial in neuropathic corneal pain and earlier statistically significant results in a 240-patient Phase 2 trial in dry eye disease. It plans to start a 120-patient Phase 2b/3 multiple-dose study of urcosimod for neuropathic corneal pain this year.

OKYO Pharma LTD disclosed that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 of the company’s ordinary shares on Nasdaq on December 15, 2025.

This purchase brings Cerrone’s total holding to 10,516,297 shares of OKYO Pharma. The company has furnished a detailed news announcement about the transaction as Exhibit 99.1 to this report.

OKYO Pharma (OKYO) reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 82,018 of the company’s ordinary shares on NASDAQ on November 21, 2025.

This additional purchase increases Cerrone’s total beneficial holding to 10,464,695 shares. The disclosure is informational in nature and does not change the company’s capital structure or operations, but it highlights further share accumulation by a key insider.

OKYO Pharma LTD reported that its Chief Executive Officer, Gary S. Jacob, Ph.D., will present at the Ophthalmology Innovation Summit (OIS) XV. His presentation is scheduled for November 22, 2025, from 8:30–9:30 AM PT in the “Anterior Innovation Showcase” session. OIS XV, held November 21–22, 2025, at the San Diego Marriott Marquis & Marina, is described as a premier annual event that brings together innovators, investors, executives, and clinicians in eye care. The summit focuses on anterior and posterior segment advances through panel discussions, company showcases, and partnering meetings, highlighting OKYO Pharma’s participation in a global forum dedicated to treatments for vision-threatening conditions.

OKYO Pharma (OKYO) filed a Form 6-K announcing that Chief Executive Officer Gary S. Jacob, Ph.D., will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria.

The related news announcement is furnished as Exhibit 99.1. The company states this exhibit is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.

OKYO Pharma reported that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 210,000 of the company’s ordinary shares on NASDAQ. Following this purchase, his total holding is 10,382,677 shares. The news announcement was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.

OKYO Pharma LTD has filed a Form 6-K to furnish a news announcement about the regulatory registration pathway and a planned 100-patient multi-center clinical trial of Urcosimod in neuropathic corneal pain. The company states that the announcement, dated September 22, 2025, is included as Exhibit 99.1 to the report. The furnished information is not deemed filed under the Securities Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

OKYO Pharma Limited filed an Amendment No. 1 to its Form 20-F for the fiscal year ended March 31, 2025 to correct an omission in the exhibits. The sole change is a revision of the Exhibit Table to include the Company’s Clawback Policy, which had been erroneously omitted from the original filing. The amendment states that no other disclosures were modified or updated and that subsequent events after the original filing are not reflected.

The filing confirms the registrant is incorporated in Guernsey, prepares financial statements under IFRS, is an emerging growth company, is listed on the NASDAQ Capital Market, and had 37,610,676 ordinary shares outstanding as of July 3, 2025. The company indicates it has filed required reports and submitted required interactive data files.